Solid-Phase Synthesis of Difficult Purine-Rich PNAs through Selective Hmb Incorporation: Application to the Total Synthesis of Cell Penetrating Peptide-PNAs.

Frontiers in Chemistry
Julien TailhadesFazel Shabanpoor

Abstract

Antisense oligonucleotide (ASO)-based drug development is gaining significant momentum following the recent FDA approval of Eteplirsen (an ASO based on phosphorodiamidate morpholino) and Spinraza (2'-O-methoxyethyl-phosphorothioate) in late 2016. Their attractiveness is mainly due to the backbone modifications which have improved the in vivo characteristics of oligonucleotide drugs. Another class of ASO, based on peptide nucleic acid (PNA) chemistry, is also gaining popularity as a platform for development of gene-specific therapy for various disorders. However, the chemical synthesis of long PNAs, which are more target-specific, remains an ongoing challenge. Most of the reported methodology for the solid-phase synthesis of PNA suffer from poor coupling efficiency which limits production to short PNA sequences of less than 15 residues. Here, we have studied the effect of backbone modifications with Hmb (2-hydroxy-4-methoxybenzyl) and Dmb (2,4-dimethoxybenzyl) to ameliorate difficult couplings and reduce "on-resin" aggregation. We firstly synthesized a library of PNA dimers incorporating either Hmb or Dmb and identified that Hmb is superior to Dmb in terms of its ease of removal. Subsequently, we used Hmb backbone modification t...Continue Reading

References

Sep 15, 1994·Biochemical Pharmacology·V V DemidovP E Nielsen
Apr 29, 1998·Nature Biotechnology·L Good, P E Nielsen
Oct 20, 1998·Nucleic Acids Research·U GiesenP E Nielsen
Mar 15, 2006·Journal of Combinatorial Chemistry·Fayna García-MartínFernando Albericio
Jul 31, 2007·Organic Letters·Hyunil LeeSung Kee Kim
Jul 5, 2008·Organic & Biomolecular Chemistry·Frank Altenbrunn, Oliver Seitz
Jan 27, 2009·Chemical Society Reviews·Stephen B H Kent
Mar 17, 2009·Annals of Neurology·Toshifumi YokotaEric Hoffman
Jan 14, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·HaiFang YinMatthew J A Wood
Oct 28, 2010·Journal of Peptide Science : an Official Publication of the European Peptide Society·Rajendra JoshiJoern Engelmann
Oct 21, 2011·Chemical Society Reviews·Søren L PedersenKnud J Jensen
Jan 3, 2012·International Journal of Medical Sciences·Rüdiger PipkornKlaus Braun
Dec 26, 2012·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Kuo-Chien TsaoShin-Ru Shih
Feb 21, 2013·International Journal of Medical Sciences·Rüdiger PipkornKlaus Braun
Nov 1, 2013·Nucleic Acid Therapeutics·Peter JärverMichael J Gait
Jun 19, 2014·Chemical Communications : Chem Comm·Abu-Baker M Abdel-AalJohn Offer
Feb 3, 2015·Journal of Peptide Science : an Official Publication of the European Peptide Society·Julien TailhadesJohn D Wade
May 23, 2015·Cancer Biology & Therapy·David Abasiwani AlagpulinsaRobert Joseph Shmookler Reis
Aug 20, 2015·Chemical Communications : Chem Comm·Jieon LeeDal-Hee Min
Aug 3, 2017·Journal of Biotechnology·Anjali GuptaNidhi Puri

❮ Previous
Next ❯

Methods Mentioned

BETA
biosensors
transfection
electrophoresis

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.